Factors influencing the economics of biosimilars in the US

被引：16

|

作者：

Mehr, Stanton R. ^{[1
,2
]}

Brook, Richard A. ^{[3
,4
,5
]}

机构：

[1] SM Hlth Commun, Newtown, PA USA

[2] Biosimilars Review & Report, Newtown, PA USA

[3] Retrospect Anal, Newfoundland, NJ 07435 USA

[4] JeSTARx Grp, Newfoundland, NJ 07435 USA

[5] Better Hlth Worldwide, Newfoundland, NJ 07435 USA

来源：

JOURNAL OF MEDICAL ECONOMICS | 2017年 / 20卷 / 12期

关键词：

INFLIXIMAB;

D O I：

10.1080/13696998.2017.1366325

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

下载

收藏

页码：1268 / 1271

页数：4

相关论文

共 50 条

[31] Challenges and Opportunities for Biosimilars Developers in the US
Ritter, Amy
Barry, Nora
BIOPHARM INTERNATIONAL, 2012, 25 (09) : 24 - 25
[32] FDA Guides the Way to Biosimilars in the US
Drakulich, Angie
Pharmaceutical Technology, 2012, 36 (03)
[33] FDA Guides the Way to Biosimilars in the US
Drakulich, Angie
BIOPHARM INTERNATIONAL, 2012, 25 (03) : 8 - 8
[34] US PAYER EXPECTATIONS FOR REIMBURSEMENT OF BIOSIMILARS
Malik, A. N.
Keeping, K.
Fletcher-Louis, M.
VALUE IN HEALTH, 2015, 18 (07) : A545 - A545
[35] Biosimilars markets: US and EU compared
Bird, Eleanor
Derbyshire, Michelle
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2020, 9 (02): : 90 - 92
[36] First biosimilars trickle into US pathway
不详
NATURE BIOTECHNOLOGY, 2014, 32 (09) : 855 - 855
[37] Perceptions of US Community Rheumatologists on Biosimilars
Radtchenko, Janna
Smith, Yolaine
Kish, Jonathan
Feinberg, Bruce
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[38] Biosimilars Approvals in the US: The Path Forward
Engel, John M.
BIOPHARM INTERNATIONAL, 2010, 23 (09) : 46 - +
[39] Demonstrating interchangeability and biosimilarity for US biosimilars
Derbyshire, Michelle
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2016, 5 (03): : 139 - 139
[40] Barriers to market uptake of biosimilars in the US
Felix, Abigail E.
Gupta, Anumeha
Cohen, Joshua P.
Riggs, Kim
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2014, 3 (03): : 108 - 115

← 1 2 3 4 5 →